Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Aviance Capital Partners LLC

Aviance Capital Partners LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,230 shares of the biopharmaceutical company’s stock after acquiring an additional 569 shares during the period. Aviance Capital Partners LLC’s holdings in Gilead Sciences were worth $1,335,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Etesian Wealth Advisors Inc. grew its position in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares in the last quarter. Financial Counselors Inc. grew its holdings in shares of Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the period. Steph & Co. lifted its holdings in Gilead Sciences by 1.9% during the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 142 shares in the last quarter. Finally, First Affirmative Financial Network boosted its position in Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GILD. Wells Fargo & Company reduced their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday, April 24th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price target on shares of Gilead Sciences in a research note on Monday. Finally, Barclays dropped their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 29th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $83.47.

Gilead Sciences Trading Up 0.0 %

NASDAQ:GILD opened at $68.64 on Tuesday. The company has a market capitalization of $85.52 billion, a PE ratio of 190.67, a P/E/G ratio of 2.92 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The stock’s 50 day moving average price is $65.98 and its 200 day moving average price is $72.51. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period last year, the firm posted $1.37 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, research analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.